TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion (TEMPO-1)
This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours. Anyone diagnosed with a minor stroke faces the possibility of long-term disability and even death, regardless of treatment. Stroke symptoms such as weakness, difficulty speaking and paralysis may improve or worsen over the hours or days immediately following a stroke. The purpose of this research trial is to study the effects of a clot-dissolving drug, tenecteplase (TNK-tPA), as a treatment for patients who arrive within twelve hours from stroke onset. This study is attempting to see if TNK-tPA given through a vein in the arm (intravenous) to patients is a safe treatment for stroke patients. Neither the safety nor the effectiveness of this treatment has been proven yet.
This trial will be conducted at several site in Canada.
Dr Michael Hill and Dr. Shelagh Coutts are the Principal Investigators of this trial, coordinated at the University of Calgary, Foothills Medical Centre.
|Study Design:||Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase 2, Prospective, Two Cohort, Dose-escalation, Safety and Feasibility Study of Thrombolysis for Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion Using TNK-tPA|
- Proportion of serious bleeding events [ Time Frame: Up to 12 weeks ] [ Designated as safety issue: Yes ]The primary safety outcome will be the rate of expected serious adverse events associated with study drug. This will be defined as the number patients with at least one SAE divided by the number of patients enrolled by dose-tier. Thus, the unit of analysis will be the patient and not the SAE.
- NIHSS 0 and mRS 0 and Barthel Index > 90 [ Time Frame: 90 days ] [ Designated as safety issue: No ]Complete neurological and functional recovery at 30 days defined as: NIHSS 0 and mRS 0 iii)Complete neurological and functional recovery at 90 days defined as: a. NIHSS 0-1 and mRS 0-1 and Barthel Index > 90
- Recanalization on follow-up CTA 4-8 hours post-treatment [ Time Frame: 4-8 hours ] [ Designated as safety issue: No ]Recanalization defined on follow-up 4-8 hour CTA
|Study Start Date:||July 2012|
|Estimated Study Completion Date:||July 2014|
|Estimated Primary Completion Date:||July 2014 (Final data collection date for primary outcome measure)|
Experimental: TNK-tPA Tenecteplase
This is an open-label trial, all patients will receive tenecteplase.
Tenecteplase will be given to the patient as an intravenous bolus over 1- 2 minutes within 90 minutes of the first slice of the CTA. This is an open-label trial, all patients will receive tenecteplase, either tier 1 or tier 2 dosage.
Other Name: TNK-tPA
The primary objective of TEMPO-1 is to demonstrate the safety and feasibility of using TNK-tPA (tenecteplase), a thrombolytic agent that is relatively novel to the treatment ischemic stroke but well-established in the treatment of myocardial infarction, to treat minor ischemic stroke patients with proven acute symptomatic occlusions. Up to 80% of ischemic stroke is minor and initially non-disabling. These patients present with a transient ischemic attack (TIA) or minor stroke.An overwhelming majority are not treated with thrombolysis as they are considered "too good to treat" by most physicians.
TEMPO-1 will enroll patients within a 12 hour time window with a NIHSS score of <6 and an ASPECTS >5. Patients must have an intracranial occlusion on CTA. Study drug must be administered within 90 minutes from the first slice of CTA. This is an open- label, multi-centre trial, dose- escalated trial. A total of 50 patients will be enrolled, 25 per tier. There will two dose tiers at 0.1 mg/kg and 0.25 mg/kg. Advancement to the second dose-tier will be dependent upon safe completion of the 1st dose tier and the approval of the DSMB.
Patients will undergo a study CT angiogram of the intracranial circulation between 4-8 hours after treatment to determine the biological effect of the drug - whether the occluded artery has recanalized or not. Patients will be assessed at 24 and 48 hours, and at Days 5, 30, and 90.
|Contact: Michael D Hill, MDemail@example.com|
|Contact: Shelagh B Coutts, MDfirstname.lastname@example.org|
|University of Calgary||Recruiting|
|Calgary, Alberta, Canada, T2N 2T9|
|Contact: Carol C Kenney, RN, CCRP 403-944-4286 Tempo1@ucalgary.ca|
|Contact: Michelle R Wright 403-944-8065 Tempo1@ucalgary.ca|
|Principal Investigator: Michael D Hill, MD, FRCPC|
|Principal Investigator: Shelagh B Coutts, MD, FRCPC|
|Principal Investigator:||Michael D Hill, MD,MSc FRCPC||University of Calgary|
|Principal Investigator:||Shelagh B Coutts, MD,FRCPC||University of Calgary|